Amgen Inc. and Novartis International, a Swiss biopharmaceutical company, have launched a new clinical trial to assess the effectiveness of their co-developed drug for the prevention of Alzheimer’s disease in high-risk patients. ...

Subscribe to get the full story.


Are you a subscriber? Sign In